Codon

DECEMBER 10, 2023

Predictive Models A “ sequence-to-function ” predictive model – an algorithm that determines a protein’s likely function solely by looking at the DNA sequence encoding it – is the natural successor to AlphaFold2. A predictive model for sequence-to-expression would raise the “hit” rates.

Protein Expression 99

Protein Expression Laboratories DNA Engineering 99

Drug Target Review

JULY 5, 2023

A good introduction to the use of CHO cells for biotherapeutics production can be found in an article commemorating the 20th anniversary of the approval of a product produced using CHO cells. These sites are typically in areas of open chromatin and associated with highly expressed genes.

Engineering 105

Engineering DNA Laboratories Production 105

Codon

DECEMBER 10, 2023

Predictive Models A “ sequence-to-function ” predictive model – an algorithm that determines a protein’s likely function solely by looking at the DNA sequence encoding it – is the natural successor to AlphaFold2. A predictive model for sequence-to-expression would raise the “hit” rates.

Protein Expression 81

Protein Expression Laboratories DNA Engineering 81

DrugBank

JULY 24, 2024

The success of PARP inhibitors in BRCA-mutant ovarian and breast cancers validates this approach, and similar strategies are being tested for other DNA repair enzymes. By inhibiting "passenger" gene products like PRMT5 in MTAP-null cells, researchers can selectively target cancer cells while minimizing harm to healthy cells.

Small Molecule 98

Small Molecule Drugs Clinical Trials Therapies 98

Broad Institute

AUGUST 24, 2022

Data from standard DNA and RNA sequencing approaches were integrated with mass spectrometry-based proteomics and phosphoproteomic analyses to derive more complete molecular portraits of treatment-responsive versus treatment-resistant tumors. These data suggest a multi-omics predictor for chemotherapy response is within reach.

DNA 52

DNA Treatment Protein Expression Protein Production 52

Drug Target Review

SEPTEMBER 10, 2024

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. Early Tox material generation still requires a product-specific activity assay in place for testing and comparison against the clinical material.

Drug Development 64

Drug Development Clinical Supply Production FDA 64

Drug Target Review

MAY 4, 2023

Using GWAS, scientists identified areas of the genome important for producing fetal haemoglobin, a target based on its promise for reversing sickle cell anaemia, but they did not know which exact variant drives its production.

Disease 52

Disease Small Molecule Protein Expression Research 52